thebench.bio #1 Ecosystem for the Bio-Tech Industry

Regulatory Daily Summary

Regulatory Daily Summary: What Happened on November 7, 2026

FDA expands Rybrevant Faspro to previously treated head and neck cancer

CMS finalized Medicare negotiation rules for new drug formulations, while biotech groups sued to block a separate pricing pilot.

  • Updated
  • Read from 10 articles, 8 publications
  • P B P P +2

Covers November 6 and November 7. There was no summary on November 6.

Today in brief

The FDA granted accelerated approval to Johnson & Johnson’s Rybrevant Faspro for some adults with recurrent or metastatic head and neck cancer after chemotherapy and immunotherapy.123 CMS finalized rules that could bring some reformulated drugs into Medicare’s negotiated prices earlier. Biotech trade groups also sued to stop a separate Medicare pricing pilot.45

Rybrevant Faspro wins accelerated approval in head and neck cancer

The FDA approved Rybrevant Faspro for adults whose recurrent or metastatic head and neck squamous cell cancer worsened during or after platinum chemotherapy and treatment with a PD-(L)1 inhibitor.123 The label excludes HPV-associated oropharyngeal cancer, and this is the drug’s first approved use outside lung cancer.23

The decision relied on the single-arm OrigAMI-4 study, in which 42% of 102 patients responded and 15% had complete responses.23 Among responders, 56% had a response lasting more than six months.23

Serious adverse reactions occurred in 39% of patients. Fatal adverse reactions occurred in 6%, including sudden death in 2%.23 The accelerated approval uses response rate and response duration as surrogate measures. Continued approval may depend on confirmation of clinical benefit in the Phase 3 OrigAMI-5 trial.23

CMS codifies negotiation rules for reformulated medicines

CMS finalized rules for Medicare drug-price negotiation, including how it will handle some fixed-combination formulations that change a drug’s administration route.4 If the same application holder adds an ingredient that enables a different route, CMS will group qualifying versions for drug selection and negotiation.4

CMS gave the example of a negotiated price for a selected biologic also applying to its hyaluronidase formulation from 2029, rather than potentially waiting until 2039.4 CMS said the policy is intended to prevent manufacturers from shifting patients to a new version to avoid the maximum fair price.4

The rule applies to drug selection and negotiation in 2027 for prices effective in 2029. The current guidance-based approach continues through 2028.4 CMS also set a temporary price floor for qualifying small biotech drugs in 2029 and 2030, at 66% of the drug’s inflation-adjusted 2021 average non-federal manufacturer price.4

Commenters argued that subcutaneous reformulations require distinct clinical, manufacturing, pharmacokinetic, and regulatory work, with particular effects for smaller biotech and delivery-technology companies.4 CMS described the policy as narrow and said it would monitor implementation and consider adjustments as it gains experience.4

Also worth knowing

  • The European Commission expanded Jyseleca’s authorization to adults with active radiographic or non-radiographic axial spondyloarthritis who have not responded adequately to conventional therapy.6

  • P

    The UK is testing a shorter appraisal process for new medicines through NICE.7

  • The UK medicines regulator set a 2026–2030 plan to widen patient and public input into drug and medical-device policy, safety reviews, and emerging-technology regulation.8

  • The European Medicines Agency’s veterinary committee recommended marketing authorizations for five medicines, including Scovella, the first recommendation under the EU limited-market framework.9

  • Inovio received an FDA designation for its DNA-based therapy.10

Also published